Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Iovance Biotherapeutics Stock Is Crashing Today

By George Budwell - Sep 6, 2018 at 3:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A key clinical update sent Iovance's shares spiraling downward today.

What happened

Shares of the clinical-stage cancer immunotherapy company Iovance Biotherapeutics ( IOVA -6.02% ) cratered today in response to a presentation at the H.C. Wainwright Global Investor Conference in New York City yesterday. What specific event triggered this downward spiral?

Investors apparently aren't thrilled with the company's clinical update for its mid-stage tumor-infiltrating lymphocyte (TIL) therapy, C-144-01, in patients with advanced skin cancer who have been previously treated with an anti-PD-1 and anti-CTLA-4 checkpoint inhibitor. As of 2:29 p.m. EDT on Thursday, Iovance's shares were down by a whopping 27%.  

A tumor cell dividing.

Image source: Getty Images.

So what

The top headline here is that C-144-01 failed to produce an objective response rate on par with Bristol-Myers Squibb's ( BMY 1.64% ) combo therapy consisting of Opdivo and Yervoy for this indication (40% vs. 50%). Leading into this update, however, Wall Street was hoping that C-144-01 would prove to be a superior therapy to Bristol's cocktail. While it's still early days for C-144-01, this less-than-stellar result may force the company to rethink its clinical strategy.   

Now what

On the plus side, this key clinical update only included a handful of patients (n = 10). So, the data might perk up as more patients are evaluated. Iovance also has a fairly broad pipeline assessing TIL therapies as both solo treatments, as well as in combination settings with various checkpoint inhibitors. This dramatic pullback, therefore, might turn out to be temporary in nature. Even so, this speculative biotech stock is still probably only well suited for investors comfortable with exceedingly high levels of risk.

 
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Iovance Biotherapeutics, Inc. Stock Quote
Iovance Biotherapeutics, Inc.
IOVA
$16.55 (-6.02%) $-1.06
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$56.32 (1.64%) $0.91

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
640%
 
S&P 500 Returns
139%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.